Article
Envision Pharma Group
Evolving Role of MSL Field Support for Clinical Trials
Summary
In this episode, Tom Caravela is joined by Khalil Ahmed to explore the integral role of Medical Science Liaisons (MSLs) in clinical trials. Khalil shares his background and discusses the significant impact MSLs have on site selection, recruitment, and training. The conversation delves into the financial implications of clinical trial delays, highlighted by a Lipitor case study, and underscores the value MSLs bring to the process. Key skills and the evolving roles of MSLs are examined, emphasizing the importance of early involvement and effective communication. The episode also touches on career growth opportunities for MSLs through active participation in clinical trials.
Khalil Ahmed, Vice President, Medical Affairs, Europe & APAC at Syneos Health discusses the evolving role of MSL Field Medical Support for Clinical Trials
This episode is sponsored by Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. The worlds largest contract commercial organization and 3rd largest CRO. Syneos translates unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. For more details, please visit syneoshealth.com
Khalil shares….
👉 The optimum time to bring MSLs into the clinical trial process
👉 What value MSLs bring to clinical trials
👉 MSL involvement, light touch or full support
👉 Risks and words of caution for MSLs in trial support
👉 Skills MSL need to support clinical trials
Medical Science Liaisons, clinical trials, MSL involvement, Syneos Health, Khalil Ahmed
Related Topics
You May Also Like
Envision Pharma Group
Article
Garth W. Strohbehn, MD, MPhil, Allen S. Lichter, MD and Mark J. Ratain, MD
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
Article
Anushka Walia, Alyson Haslam, Vinay Prasad
FDA validation of surrogate endpoints in oncology: 2005–2022
Article
Sarah M. Dermody, Andrew G. Shuman
Implications of Research Biopsies in Clinical Trials
Article
Kyle A. Dymanus BS, Mohit Butaney MBBS, Diana E. Magee MD, MPH, MSc, Amanda E. Hird MD, MSc, Amy N. Luckenbaugh MD, Merry W. Ma MD, PhD, Mary E. Hall MD, Heather L. Huelster MD, Aaron A. Laviana MD, MBA, Nancy B. Davis MD, Martha K. Terris MD, Zachary Kla
Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study
Article
Nora Hutchinson, MD, CM, MPhil, Benjamin Carlisle, PhD, Adelaide Doussau, MD, PhD